Evaluation in a cohort of patients with NF2-related VS undergoing anti-VEGF therapy demonstrated that there was an association between baseline tumour volume and low-level permeability (Ktrans) changes within the normal-appearing brain and that, within the tumour microenvironment, this new approach allowed for concomitant evaluation of blood flow and permeability changes, with the tumoural capillary permeability-surface area product demonstrating the most pronounced reduction at 90 days. This evidence concerns the gene VEGFA and neoplasm.